New Drug Approvals Archive

Get news by email or subscribe to our news feeds.

November 2005

November 2

Exjade (deferasirox) Dispersible Tablets

Date of Approval: November 2, 2005
Company: Novartis
Treatment for: Hemosiderosis, Iron Overload

Exjade (deferasirox) is a once-daily oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions, and non-transfusion-dependent thalassemia.

Exjade (deferasirox) FDA Approval History

January 23

Exjade (deferasirox)

New Indication Approved: January 23, 2013

Exjade (deferasirox) FDA Approval History

Hide
(web2)